Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-12
2007-06-12
Owens, Amelia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S335000, C560S106000, C514S345000, C514S352000, C514S543000, C514S544000, C514S532000
Reexamination Certificate
active
10958089
ABSTRACT:
Prodrugs of propofol, methods of making prodrugs of propofol, pharmaceutical compositions of prodrugs of propofol and methods of using prodrugs of propofol and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as migraine headache pain and post-chemotherapy or post-operative surgery nausea and vomiting are disclosed herein.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4765539 (1988-08-01), Noakes et al.
patent: 4962885 (1990-10-01), Coffee
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5950619 (1999-09-01), van der Linden et al.
patent: 5954047 (1999-09-01), Armer et al.
patent: 5970974 (1999-10-01), van Der Linden et al.
patent: 6254853 (2001-07-01), Hendler et al.
patent: 6362234 (2002-03-01), Hendler
patent: 2001/0025035 (2001-09-01), Stella et al.
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/12285 (1994-06-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 94/14543 (1994-07-01), None
patent: WO 95/26234 (1995-10-01), None
patent: WO 95/26235 (1995-10-01), None
patent: WO 95/32807 (1995-12-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 99/58555 (1999-11-01), None
patent: WO 00/48572 (2000-08-01), None
patent: WO 00/54588 (2000-09-01), None
patent: WO 02/13810 (2002-02-01), None
Hattori, T et al ‘Accelerating effect of meta substituents in the ester-mediated nucleophilic aromatic substitution reaction’ CA 130:109862 (1998).
Hattori, T et al ‘1-arylfluorenols: convenient preparation via the ester-mediated nucleophilic aromatic substitution portocol, facil racemization, and intrinsic chiral induction ability’ CA 129:330529 (1998).
Trapani, G et al ‘Propofol analogs. Synthesis, relationships between structure and affinity of GABAA receptor in rat brain, and differential electrophysiological profile at recombinant human GABAA receptors’ CA 128:252919 (1998).
Hattori, T et al ‘Convenient synthesis of triarylamines via ester-mediated nucleophilic aromatic substitution’ CA 125:33232 (1996).
Hattori, T et al ‘Facil construction of the 1-phenylnaphthyl skeleton via an ester-mediated nucleophilic aromatic substitution reaction. Applications to the synthesis of phenylnaphthalide lignans’ CA 122:239427 (1995).
Pop, E et al ‘A theoretical study of the hydrolysis of some sterically hindered phenolic esters’ CA 118:168494 (1993).
Trapani, Propofol in anesthesia. Mechanism of action, structure-activity relationships, and drug delivery, (2000), PMID:10637364.
Alderman, “A Review of Cellulose Ethers in Hydrophylic Matrices for Oral Controlled-Release Dosage Forms,”Int. J. Pharm. Tech.&Prod. Mfr. 1984, 5(3) 1-9.
Anderson et al., “α-Amino Acid Phenolic Ester Derivatives: Novel Water-Soluble General Anesthetic Agents Which Allosterically Modulate GABAAReceptors,”J. Med. Chem. 2001, 44, 3582-3591.
Bamba et al., “Release Mechanisms in Gelforming Sustained Release Preparations,”Int. J. Pharm. 1979, 2, 307.
Banaszczyk et al., “Propofol Phosphate, a Water-Soluble Propofol Prodrug: In Vivo Evaluation,”Anesth. Analg. 2002, 95, 1285-1292.
Borgeat et al., “Preliminary Communication: Adjuvant Propofol Enables Better Control of Nausea and Emesid Secondary to Chemotherapy for Breast Cancer,”Can. J. Anaesth. 1994, 41, 1117-1119.
Borgeat et al., “Propofol Improves Patient Comfort During Cysplatin Chemotherapy,”Oncology1993, 50, 456-459.
Briggs et al., “An Adverse Rection to the Administration of Disoprofol (Diprvan),”Anaesthesia1982, 37, 1099-1101.
Brooker et al., “Propofol Maintenance to Reduce Postoperatiove Emesis in Thyroidectomy Patients: A Group Sequential Comparison with Isoflurane/Nitrous Oxide,”Anaesth. Intensive Care1998, 26, 625-629.
Brown et al., “Role of Propofol in Refractory Status Epilepticus,”Pharmacother. 1998, 32, 1053-1059.
Chatterjee et al., “Molecular Mechanism Of The Intestinal Biotin Transport Process,”Am. J. Physiol. 1999, 277, C605-C613.
Collins et al., “Scanning Mutagenesis Of The Putative Transmembrane Segments Of Kir2.1, An Inward Rectifier Potassium Channel,”Proc. Natl. Acad. Sci. 1997, 13:5456-5460.
De la Cruz et al., “The Effect of Propofol on Oxidative Stress in Platelets from Surgical Patients,”Anesth. Analg. 1999, 89, 1050-1055.
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” 1989,Ann. Neurol. 25:351-356.
Gan et al., “Determination of Plasma Concentrations of Propofol Associated with 50% Reduction in Postoperative Nausea,”Anesthesiology, 1997, 87, 779-784.
Halestrap et al., “The Proton-Liked Monocarboxylate Transporter (MCT) family: Structure, Function and Regulation,”Biomedical J., 1999, 343, 281-299.
Hasan et al., “Comparison of the Effects of the Propofol and Thiopental on the Pattern of Maximal Electroshock Seizures in a Rat,”Pharmacol. Toxicol. 1994, 74, 50-53.
Hashimotto et al., “Abnormal Activity in the Globus Pallidus in the Off-Period Dystonia,”Annals. of Neurology, 2001, 49, 242-275.
Holtkamp et al., “Propofol In Subanesthetic Doses Terminates Status Epilepticus In A Rodent Model,”Ann. Neurol. 2001, 49, 260-263.
Howard et al., “Intercerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” 1989,J. Neurosurg. 71:105-112.
Krusz et al., “Intravenous Propofol: Unique Effectiveness in Treating Intractable Migraine,”Headache2000, 40, 224-230.
Kuisma et al., “Propofol in Prehospital Treatment of Convulsive Status Epilepticus,”Epilepsia1995, 36, 1241-1243.
Langer et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” 1983,J Macromol. Sci. Rev. Macromol Chem. 23:61.
Langley et al., “Propofol: A Review of Its Pharamcodynamic and Pharmacokinetic Properties and Use as an Intravenous Anaesthetic,”Drugs1988, 35, 334-372.
Levy et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release of Diphosphonate,” 1985,Science228: 190.
Murphy et al., “The Antioxidant Potential of Propofal (2,6-Diisopropylphenol),”Br. J. Anaesth. 1992, 68, 613-618.
Peduto et al., “Biochemical and Electrophysiologic Evidence That Propofol Enchances GABAergic Transmission in the Rat Brain,”Anesthesiology1991, 75, 1000-1009.
Phelps et al., “Propolol in Chemotherapy-Associated Nausea and Vomiting,”Ann. Pharmacother. 1996, 30, 290-292.
Picard et al., “Prevention of Pain on Injection with Propofol: A Quantitative Systematic Review,” 2000, 90, 963-969.
Pop et al., “Synthesis and Preliminary Pharmacological Evaluation of Some Chemical Delivery Systems of 2,6-Diisopropylphenol (Propofol),”Med. Chem. Res. 1992, 2, 16-21.
Prasad et al., “Molecular and Functional Characterization of the Intestinal Na1-Dependent Multivitamin Transporter,”Arch. Biochem. Biophys. 1999, 366, 95-106.
Prasad et al., “Cloning and Functional Expression of a cDNA Encoding a Mammalian Sodium-dependent Vitamin Transporter Mediating the Uptake of Pantothenate, Biotin, and Lipoate,”2J. Biol. Chem. 1998, 273, 7501-7506.
Raleigh et al., “Pharmacokinetics of Isotretinoin (ISO) in Rats Following Oral Dosing or Aerosol Inhalation,”British J. Cancer, 1999, 80, Suppl. 2, 96-97.
Raleigh et al., “Searching for the Link Between Hypoxia and Poor Prognoses in Human Tumors,”Proc. Amer. Assoc. Cancer Research Annual Meeting, 1999, 40, 39.
Raoof et al., “In Vivo Assessment of Intestinal Hepatic, and Pulmonary First Pass Metabolism of Propofol in the Rat,”Pharm. Res. 1996, 13, 891-895.
Sagara et al., “Propofol Hemisu
Gallop Mark A.
Xu Feng
Dorsey & Whitney LLP
Owens Amelia
XenoPort, Inc.
LandOfFree
Aromatic prodrugs of propofol, compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aromatic prodrugs of propofol, compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aromatic prodrugs of propofol, compositions and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3816114